191 related articles for article (PubMed ID: 3398663)
1. Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing.
Kopelman J; Budnick AS; Sessions RB; Kramer MB; Wong GY
Laryngoscope; 1988 Aug; 98(8 Pt 1):858-64. PubMed ID: 3398663
[TBL] [Abstract][Full Text] [Related]
2. [Detection of late ototoxic side effect of cisplatin by distortion otoacoustic emission (DPOAE)].
Biró K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Magy Onkol; 2006; 50(4):329-35. PubMed ID: 17216007
[TBL] [Abstract][Full Text] [Related]
3. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
4. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
Biró K
Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-based chemotherapy: Add high-frequency audiometry in the regimen.
Arora R; Thakur JS; Azad RK; Mohindroo NK; Sharma DR; Seam RK
Indian J Cancer; 2009; 46(4):311-7. PubMed ID: 19749461
[TBL] [Abstract][Full Text] [Related]
6. [Hearing assessment of children treated with Cisplatin].
Mniszek J; Bielecki I; Sobol G
Pol Merkur Lekarski; 2009 Aug; 27(158):105-8. PubMed ID: 19856874
[TBL] [Abstract][Full Text] [Related]
7. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
Freilich RJ; Kraus DH; Budnick AS; Bayer LA; Finlay JL
Med Pediatr Oncol; 1996 Feb; 26(2):95-100. PubMed ID: 8531860
[TBL] [Abstract][Full Text] [Related]
8. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration.
Reddel RR; Kefford RF; Grant JM; Coates AS; Fox RM; Tattersall MH
Cancer Treat Rep; 1982 Jan; 66(1):19-23. PubMed ID: 7198012
[TBL] [Abstract][Full Text] [Related]
9. High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics.
Ekborn A; Hansson J; Ehrsson H; Eksborg S; Wallin I; Wagenius G; Laurell G
Laryngoscope; 2004 Sep; 114(9):1660-7. PubMed ID: 15475801
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission.
Biro K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Oncology; 2006; 70(3):177-84. PubMed ID: 16757924
[TBL] [Abstract][Full Text] [Related]
11. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
12. Left-right asymmetry in hearing loss following cisplatin therapy in children--the left ear is slightly but significantly more affected.
Schmidt CM; Knief A; Lagosch AK; Deuster D; am Zehnhoff-Dinnesen A
Ear Hear; 2008 Dec; 29(6):830-7. PubMed ID: 18772725
[TBL] [Abstract][Full Text] [Related]
13. [The ototoxicity of cisplatin: a clinical study].
Vantrappen G; Rector E; Debruyne F
Acta Otorhinolaryngol Belg; 1990; 44(4):415-21. PubMed ID: 2093285
[TBL] [Abstract][Full Text] [Related]
14. [Ototoxicity of cisplatin in children with malignant diseases].
Hadjilaskari P; Fengler R; Hartmann R; Henze G
Klin Padiatr; 1989; 201(4):316-21. PubMed ID: 2779137
[TBL] [Abstract][Full Text] [Related]
15. Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration.
Waters GS; Ahmad M; Katsarkas A; Stanimir G; McKay J
Ear Hear; 1991 Apr; 12(2):91-102. PubMed ID: 2065844
[TBL] [Abstract][Full Text] [Related]
16. Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer.
Zuur CL; Simis YJ; Verkaik RS; Schornagel JH; Balm AJ; Dreschler WA; Rasch CR
Radiother Oncol; 2008 Oct; 89(1):38-43. PubMed ID: 18706728
[TBL] [Abstract][Full Text] [Related]
17. High-dose cisplatin treatment: hearing loss and plasma concentrations.
Laurell G; Jungnelius U
Laryngoscope; 1990 Jul; 100(7):724-34. PubMed ID: 2362532
[TBL] [Abstract][Full Text] [Related]
18. [Relations between pure-tone threshold and discrimination of monosyllables in inner ear high-frequency hearing disorders].
Battmer RD; Lehnhardt E
HNO; 1984 Feb; 32(2):69-73. PubMed ID: 6706703
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin administration to gynecologic cancer patients. Long-term effects on hearing.
Laurell G; Beskow C; Frankendal B; Borg E
Cancer; 1996 Oct; 78(8):1798-804. PubMed ID: 8859195
[TBL] [Abstract][Full Text] [Related]
20. Audiometric patterns in ototoxicity of intra-arterial Cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Rasch CR; Tange RA; Balm AJ; Dreschler WA
Audiol Neurootol; 2006; 11(5):318-30. PubMed ID: 16983183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]